Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 1;40(17):3087–3100. doi: 10.1038/s41388-021-01754-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Measurement of LNCaP cell growth and representing cell pictures after 9 d treatment with increasing concentrations (5 µM, 10 µM, 20 µM) of the specific MAO-A inhibitor clorgyline. Data represent mean + SE from four independent experiments (one-way ANOVA and correction for multiple testing using Dunnett´s comparison test; *, P < 0.05; ***, P < 0.001). B Measurement of cell cycle distribution and percentage of apoptotic cells, as well as western blot analysis for p21 protein expression after treatment with increasing clorgyline concentrations for 9 d. Data represent mean + SE from four independent experiments (one-way ANOVA and correction for multiple testing using Dunnett´s comparison test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). C LNCaP and LNCaPabl cell growth measurement after 9 d treatment with 10 µM clorgyline alone or in combination with 2.5 µM enzalutamide, apalutamide, or darolutamide. Data represent mean + SE from at least three independent experiments (one-way ANOVA and correction for multiple testing using Bonferroni´s comparison test; **, P < 0.01; ***, P < 0.001). D LNCaP, LNCaPabl, and abl-Enza cell growth measurement after 9 d treatment with 10 µM clorgyline alone or in combination with 2.5 µM abiraterone. Data represent mean + SE from at least three independent experiments (one-way ANOVA and correction for multiple testing using Bonferroni´s comparison test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). E LNCaP, LNCaPabl, abl-Enza, abl-Abi cell growth measurement after 9 d treatment with 10 µM clorgyline alone or in combination with 0.4 nM (for LNCaP, LNCaPabl, abl-Enza) or 0.75 nM (for abl-Abi) docetaxel or cabazitaxel. Data represent mean + SE from at least three independent experiments (one-way ANOVA and correction for multiple testing using Bonferroni´s comparison test; *, P < 0.05; **, P < 0.01; ***, P < 0.001).